Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), yesterday announced the US launch of Glatopa, the first generic version of Teva Pharmaceutical Industries’ (NYSE: TEVA) Copaxone(glatiramer acetate injection) 20mg/ml one-time-daily multiple sclerosis therapy.
Glatopa, developed in collaboration with Momenta Pharmaceuticals (Nasdaq: MNTA) and produced entirely in the USA, is indicated for the treatment of patients with relapsing forms of MS, including those who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS.
"Sandoz, together with Momenta, is proud to announce the US market launch of a fully substitutable generic version of this important therapy, following FDA approval" said Peter Goldschmidt, president of Sandoz US.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze